Meeting
2018 Genitourinary Cancers Symposium
A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).
Authors
Lauren Christine Harshman
Dana-Farber Cancer Institute, Boston, MA
Lauren Christine Harshman , Maneka Puligandla , Naomi B. Haas , Mohamad Allaf , Charles G. Drake , David F. McDermott , Sabina Signoretti , David Cella , Rajan T Gupta , Rupal Satish Bhatt , Eliezer Mendel Van Allen , Toni K. Choueiri , Primo Lara Jr., Anil Kapoor , Daniel Yick Chin Heng , Brian M. Shuch , Michael A.S. Jewett , Daniel J. George , M. Dror Michaelson , Michael Anthony Carducci
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT03055013
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr TPS710)
DOI
10.1200/JCO.2018.36.6_suppl.TPS710
Abstract #
TPS710
Poster Bd #
L17
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).
First Author: Lauren Christine Harshman
Poster
2020 ASCO Virtual Scientific Program
PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).
First Author: Naomi B. Haas
Poster
2020 Genitourinary Cancers Symposium
PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).
First Author: Lauren Christine Harshman
Poster
2019 ASCO Annual Meeting
PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).
First Author: Lauren Christine Harshman